Pasado y presente del tratamiento frente a la COVID-19

  1. Quintanilla Carrillo, Belen 1
  2. López Zúñiga, Miguel Ángel 2
  3. López Ruz, Miguel Ángel 2
  1. 1 Universidad de Granada
    info

    Universidad de Granada

    Granada, España

    ROR https://ror.org/04njjy449

  2. 2 Hospital Universitario Virgen de las Nieves
    info

    Hospital Universitario Virgen de las Nieves

    Granada, España

    ROR https://ror.org/02f01mz90

Revista:
Actualidad médica

ISSN: 0365-7965

Ano de publicación: 2023

Tomo: 108

Número: 817

Páxinas: 166-184

Tipo: Artigo

DOI: 10.15568/AM.2023.817.REV02 DIALNET GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Actualidad médica

Resumo

Desde el inicio de la pandemia por COVID-19 en diciembre de 2019 se han ido proponiendo y utilizando numerosos fármacos en un intento de hacer frente a esta nueva enfermedad, con frecuentes cambios y actualizaciones en las guías de tratamiento y sus recomendaciones. Así pues, este trabajo se plantea con el objetivo de mostrar cómo ha sido la evolución del tratamiento de la COVID-19 a lo largo de este periodo. Para ello, se llevó a cabo una revisión de la literatura disponible en Pubmed, MedRxiv y las guías de tratamiento WHO, NIH y NICE. En base a la información obtenida de estas fuentes se concluye que de todos los medicamentos propuestos, tan solo los corticoides, Remdesivir y Tocilizumab han mostrado algún beneficio en los estudios realizados en pacientes con COVID-19; mientras que Cloroquina, Hidroxicloroquina y Lopinavir/ritonavir, fármacos muy utilizados al inicio, han quedado totalmente descartados. Por su parte, Anakinra, Baricitinib y Colchicina han mostrado un potencial beneficio en los primeros estudios, aunque todavía no se tiene una clara evidencia de su eficacia que permita su recomendación como tratamiento en este tipo de pacientes. En cuanto a la anticoagulación, no hay evidencia que justifique el uso de dosis terapéuticas o intermedias en pacientes hospitalizados con COVID-19, por lo que a día de hoy se recomienda la administración de dosis profilácticas

Referencias bibliográficas

  • Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1317-1329.
  • Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier JM, Lafaie L, et al. Vitamin D and survival in COVID-19 patients: A quasi-experimental study. J Steroid Biochem Mol Biol. 2020 Nov;204:105771.
  • Annweiler G, Corvaisier M, Gautier J, Dubée V, Legrand E, Sacco G, et al. Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study. Nutrients. 2020 Nov 2;12(11):3377.
  • Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H, et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int J Infect Dis. 2021 Feb;103:288-296.
  • Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 – Final Report. N Engl J Med. 2020 Nov 5;383(19):1813-1826.
  • Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al; CloroCovid-19 Team. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020 Apr 24;3(4):e208857.
  • Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799.
  • Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. Chinese.
  • Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxycloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020.03.22.20040758.
  • Clinical management of COVID-19-World Health Organization. Interim guidance. May 27, 2020. Available from: https://apps.who.int/iris/rest/bitstreams/1278777/retrieve. Accessed [05.04.2021]
  • Clinical management of COVID-19-World Health Organization. Interim guidance. January 25, 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. Accessed [08.04.2021]
  • Clinical management of COVID-19-World Health Organization. Interim guidance. January 25, 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. Accessed [08.04.2021]
  • CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021 Jan 22:S2213-2600(20)30556-7.
  • Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. FDA. May 01, 2020. [Internet] Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment Accessed [10.04.2021]
  • Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. FDA. June 15, 2020. [Internet] Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed [05.04.2021]
  • Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. NIH. Available from: https://www.covid19treatmentguidelines.nih.gov/. Accessed [08.04.2021]
  • Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. NIH. Available from: https://www.covid19treatmentguidelines.nih.gov/. Accessed [08.04.2021]
  • COVID-19 rapid guideline: Managing COVID-12. NICE guideline. March 23, 2021. Available from: https://www.nice.org.uk/guidance/ng191/resources/fully-accessible-version-of-the-guideline-pdf-pdf-9078468301 Accessed [14.04.2021]
  • Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al; GRECCO-19 investigators. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e2013136.
  • Dequin PF, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et al; CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1298-1306.
  • Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”. J Steroid Biochem Mol Biol. 2020 Oct;203:105751.
  • Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73.
  • Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949.
  • Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 Nov 5;383(19):1827-1837.
  • Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 Preliminary report. medRxiv 2021. 01.07.21249390.
  • Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Jun 11;382(24):2327-2336.
  • Guia NIH: tratamiento de COVID-19. Uso de fármacos específicos en pacientes con COVID-19. Available from: https://empendium.com/manualmibe/covid19/237133,guias-nih-tratamiento-de-covid-19-uso-de-farmacos-especificos-en-pacientes-con-covid-19. Accessed [08.04.2021]
  • Hariyanto TI, Halim DA, Jodhinata C, Yanto TA, Kurniawan A. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2021 Mar 14.
  • Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 Jan 1;181(1):32-40. Erratum in: JAMA Intern Med. 2021 Jan 1;181(1):144.
  • Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395(10238):1695-1704.
  • Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al; for the Metcovid Team. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial. Clin Infect Dis. 2020 Aug 12:ciaa1177.
  • Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V,et al; ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795-807.
  • Lemos ACB, do Espírito Santo DA, Salvetti MC, Gilio RN, Agra LB, Pazin-Filho A, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res. 2020 Dec;196:359-366.
  • London AJ, Kimmelman J. Against pandemic research exceptionalism. Science. 2020 May 1;368(6490):476-477. doi: 10.1126/science.abc1731. Epub 2020 Apr 23. PMID: 32327600.
  • Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM, et al. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021 Feb;7(1):e001455.
  • March 28, 2020 [Internet] Available from: https://www.fda.gov/media/136534/download Accessed [05.04.2021]
  • Martínez-Sanz J, Muriel A, Ron R, Herrera S, Pérez-Molina JA, Moreno S, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. Clin Microbiol Infect. 2021 Feb;27(2):238-243.
  • Mitjà O, Corbacho-Monné M, Ubals M, Tebe C, Peñafiel J, Tobias A, et al; BCN PEP-CoV-2 RESEARCH GROUP. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. Clin Infect Dis. 2020 Jul 16:ciaa1009.
  • Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al; Inhaled Interferon Beta COVID-19 Study Group. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021 Feb;9(2):196-206.
  • NIH ACTIV Trial blood thinners pauses enrollment of critically ill COVID-19 patients. NIH. December 22, 2020. Available from: https://www.nih.gov/news-events/news-releases/nih-activ-trial-blood-thinners-pauses-enrollment-critically-ill-covid-19-patients. Accessed [29.03.2021]
  • Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021 Mar;591(7848):92-98.
  • Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). Postgrad Med J. 2020 Nov 12:postgradmedj-2020-139065.
  • Recomendaciones de tromboprofilaxis y tratamiento antitrombóticoenpacientes. Sociedad Española de Trombosis y Hemostasia (SETH). 2020. Available from: https://www.covid-19.seth.es/recomendaciones-de-tromboprofilaxis-y-tratamiento-antitrombotico-en-pacientes-con-covid-19/. Accessed [29.03.2021]
  • RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704.
  • RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Nov 19;383(21):2030-2040.
  • RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 5;396(10259):1345–52.
  • RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-1645.
  • Remdesivir es el primer tratamiento que recibe la recomendación de la EMA frente a Covid-19. Diariofarma. June 25, 2020 [Internet] Available from: https://www.diariofarma.com/2020/06/25/remdesivir-es-el-primer-tratamiento-que-recibe-la-recomendacion-de-la-ema-frente-a-covid-19. Accessed [10.04.2021]
  • Rodríguez-Baño J, Pachón J, Carratalà J, Ryan P, Jarrín I, Yllescas M, et al. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clin Microbiol Infect. 2020 Aug 27:S1198-743X(20)30492-4.
  • Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021 Feb 25:NEJMoa2028700.
  • Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021 Mar 18.
  • Salah HM, Mehta JL. Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19. Am J Cardiol. 2021 Feb 19;145:170–2.
  • Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 Jan 7;384(1):20-30.
  • Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al; RCT-TCZ-COVID-19 Study Group. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 Jan 1;181(1):24-31.
  • Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020 May;39(5):405-407.
  • Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. Ann Intern Med. 2020 Oct 20;173(8):623-631. Erratum in: Ann Intern Med. 2021 Mar;174(3):435.
  • Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al; GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 Sep 15;324(11):1048-1057.
  • Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 Dec 10;383(24):2333-2344.
  • Suspension des inclusions en France dans les essais clinique evaluant l’anakinra dans la prise en charge de la COVID-19. ASNM. October 29,2020. Available from: https://ansm.sante.fr/actualites/suspension-des-inclusions-en-france-dans-les-essais-clinique-evaluant-lanakinra-dans-la-prise-en-charge-de-la-covid-19 Accessed [02.04.2021]
  • Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020 May 14;369:m1849.
  • Tardif JC, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv 2021.01.26.21250494.
  • Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al; COALITION COVID-19 Brazil III Investigators. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1307-1316.
  • Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, et al; Coalition covid-19 Brazil VI Investigators. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021 Jan 20;372:n84.
  • Vrachatis DA, Giannopoulos GV, Giotaki SG, Raisakis K, Kossyvakis C, Iliodromitis KE, et al. Impact of colchicine on mortality in patients with COVID-19: A meta-analysis. Hellenic J Cardiol. 2021 Jan 6:S1109-9666(20)30285-2.
  • Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395(10236):1569-1578. Erratum in: Lancet. 2020 May 30;395(10238):1694.
  • WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct 6;324(13):1330-1341.
  • WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med. 2021 Feb 11;384(6):497-511.
  • Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomed Pharmacother. 2021 Jan;133:110825.
Fonte de datos: Dialnet